Abstract 879P
Background
To screen potential biomarkers in patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with a subgroup analysis based on the patients treated with immunotherapy and examine the prognostic significance of CDKN2A mutations.
Methods
This single-center retrospective study analyzed the Foundation Medicine (FM) next-generation sequencing (NGS) data from patients with recurrent or metastatic HNSCC who underwent NGS between January 1, 2019, to December 31, 2021. The patients were grouped according to CDKN2A loss-of-function (LOF) vs. wild-type (WT). A subgroup analysis was performed on the patients treated with immunotherapy.
Results
Seventy-seven patients (62 with immunotherapy) were included. The median follow-up was 22.6 months. The median OS was 16.5 months in the CDKN2A LOF group and 30.0 months in the CDKN2A WT group (P=0.014). The female sex (HR=4.526, 95%CI: 1.934-10.180, P=0.0003) and CDKN2A LOF (HR=2.311, 95%CI: 1.156-4.748, P=0.019) were independently associated with mortality in patients with recurrent or metastatic HNCSS. In patients with immunotherapy, the median OS was 19.8 months, or 11.7 months in the CDKN2A LOF group and 22.5 months in the CDKN2A WT group (P=0.017). The female sex (HR=4.022, 95%CI: 1.417-10.710, P=0.006), CDKN2A LOF (HR=4.389, 95%CI: 1.782-11.460, P=0.002), and CPS <1 (HR=17.20, 95%CI: 4.134-79.550, P<0.0001) were independently associated with mortality in patients with recurrent or metastatic HNCSS treated with immunotherapy.
Conclusions
LOF alterations in the CDKN2A gene are independently associated with poor survival in patients with HNSCC, including those treated with immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ye Guo.
Funding
Beijing CSCO Clinical Oncology Research Foundation (NO.Y-XD2019-069,2019.07-2021.07).
Disclosure
Y. Guo: Financial Interests, Personal, Invited Speaker: Merck Serono, Roche, MSD, BMS, BeiGene. All other authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12